HS-tk gene therapy (AVAX)

N/A

Report date: 2024/09/19 13:54:09

Base Information

Drug NameHS-tk gene therapy (AVAX)
Drug Alias NameHSV1-tk gene therapy
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Herpes simplex virus vector > HSV-1 vector
Mechanisms of ActionThymidine kinase modulators
TargetsThymidine kinase
Therapy Area/IndicationsGraft vs Host DiseaseLiver NeoplasmsMelanoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAvax Technologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAvax Technologies Inc
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseLiver NeoplasmsMelanoma +[5] 

Other Information

ATC CodeN/A
Related LinksN/A